SPOTLIGHT: Phase III study of zolbetuximab+mFOLFOX6 versus placebo+mFOLFOX6 in first-line Claudin18.2(+)/HER2(-) advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)-MedSci.cn

SPOTLIGHT: Phase III study of zolbetuximab+mFOLFOX6 versus placebo+mFOLFOX6 in first-line Claudin18.2(+)/HER2(-) advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)

Shitara, K; Al-Batran, SE; Bang, YJ; Catenacci, D; Enzinger, PC; Ilson, DH; Kim, S; Lordick, F; Shah, MA; van Cutsem, E; Xu, RH; Arozullah, A; Park, JW; Ajani, JA

ANNALS OF ONCOLOGY, 2020; 31 (): S1317

科室
- - 订阅+
  - 更多科室
工具
服务